C4 Therapeutics, Inc. — Director's Dealing 2021

Aug 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-07-29

Reporting Person: Prokupets Elena (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-29	Common Stock	S	11336	$45.0042	Disposed	107238	Indirect
2021-08-02	Common Stock	S	4257	$45.0097	Disposed	102981	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	592873	Indirect

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.